TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33409867
Drug: Subcutaneous IgPro20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IgPro20 at 25 mL/h, Flow Rate Cohort
Study: 33409867
Drug: Subcutaneous IgPro20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IgPro20 at 75 mL/h, Flow Rate Cohort
Study: 33409867
Drug: Subcutaneous IgPro20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IgPro20 at 100 mL/h, Flow Rate Cohort
Study: 33409867
Drug: Subcutaneous IgPro20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IgPro20, Volume Cohort
Study: 33409867
Drug: Subcutaneous IgPro20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IgPro20, Flow Rate Cohort
Study: 33409867
Drug: Subcutaneous IgPro20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IgPro20
Study: 33409898
Drug: Vorinostat 200
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 200 mg orally twice daily continuously until progression or unacceptable toxicity
Study: 33410093
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30/70 (BIAsp 30) in an insulin pen (FlexPen)
Study: 33410109
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) and Indapamide combination
Study: 33410485
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid injection
Study: 33410523
Drug: Eltrombopag (EPAG)
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag (EPAG) plus standard immunosuppressive therapy (IST)
Study: 33410959
Drug: GTV1 before
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTV1 before RCT (mean 154.4 ml, 95% CI: 1.5-877)
Study: 33410959
Drug: GTV2 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTV2 at 40-50 Gy (mean 106.2 ml, 95% CI: 0.5-589.5)
Study: 33411824
Drug: ADRe-p intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADRe-p intervention (Adverse Drug Reaction Profile for polypharmacy)
Study: 33411897
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg subcutaneously at least 1 week before the first cycle of chemotherapy and then every 4 weeks during chemotherapy)
Study: 33413366
Drug: Insulin Sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Sensitive (IS)
Study: 33413552
Drug: Before treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before treatment (BT) group
Study: 33413583
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion for 6 hours to decrease heart rate by 20%.
Study: 33413583
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion for 6 hours.
Study: 33414259
Drug: Pharmaceutical interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical interventions (PIs) by clinical pharmacist during the PICC process
Study: 33414758
Drug: Repository Corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository Corticotropin Injection (Acthar® Gel)
Study: 33414828
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg/d) tapered off by week 24
Study: 33415416
Drug: Quizartinib dihydrochloride
Normalized name: QUIZARTINIB DIHYDROCHLORIDE
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib dihydrochloride (20, 30, and 60 mg daily)
Study: 33415656
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement device (MAD) therapy for 1 month
Study: 33415656
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement device (MAD) therapy for 6 months
Study: 33416257
Drug: Mobilization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization therapy (level + duration)
Study: 33416257
Drug: Mobilization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization therapy (duration)
Study: 33416257
Drug: Mobilization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization therapy (level)
Study: 33416500
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (10 sessions over 2 weeks and 20 sessions over 4 weeks)
Study: 33416995
Drug: Oral Symptom
Normalized name: Pamprin Multi-Symptom Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Symptom Assessment Scale (OSAS)
Study: 33417474
Drug: Risk-adapted preemptive
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-adapted preemptive tocilizumab (8-12 mg/kg)
Study: 33417511
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 mg/kg once every 3 weeks) plus Ipilimumab (3 mg/kg once every 3 weeks) for four inductions, followed by Nivolumab (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.
Study: 33417814
Drug: Antidepressant treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment, details not available
Study: 33418143
Drug: Speech Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech Therapy App (STAPP)
Study: 33420229
Drug: Everolimus daily
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus daily orally at 10 mg for 12 weeks
Study: 33420642
Drug: Fluzoparib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib (100 mg, p.o.) after meal consumption on day-1
Study: 33420642
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg (p.o.) under fasting condition from day-5 to day-9
Study: 33420642
Drug: Fluzoparib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib (100 mg, p.o.) after meal consumption on day-9
Study: 33420682
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of antithrombotic drugs used (0 to 8, interquartile range = 3-4)
Study: 33421178
Drug: Panobinostat 30
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat 30 mg and Carfilzomib 20/56 mg/m²
Study: 33422025
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment strategies for tibial shaft fractures (TSFs) including various surgical techniques and implant materials, with no specific dosage or duration mentioned.
Study: 33422025
Drug: Systemic perioperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic perioperative antibiotic prophylaxis, local antimicrobials, and timing of soft-tissue coverage.
Study: 33422139
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) at a single dose of 1 × 10
Study: 33422139
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs)
Study: 33425441
Drug: Preoperative intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative intra-arterial perfusion of epirubicin, etoposide, and oxaliplatin combined with oral chemotherapy S-1 (SEEOX) for 3, 21-day courses
Study: 33425441
Drug: Preoperative intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative intra-arterial perfusion of epirubicin, etoposide, and oxaliplatin combined with oral chemotherapy S-1 (SEEOX)
Study: 33425673
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of zoledronate
Study: 33425673
Drug: 6-monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly dosing of zoledronate
Study: 33425801
Drug: Tamsulosin HCl
Normalized name: tamsulosin HCl
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin HCl 0.2 mg in the fed state with a high-fat meal
Study: 33425801
Drug: Tamsulosin HCl
Normalized name: tamsulosin HCl
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin HCl 0.4 mg in the fed state with a high-fat meal
Study: 33425801
Drug: Tamsulosin HCl
Normalized name: tamsulosin HCl
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin HCl 0.4 mg in the fasted state
Study: 33427211
Drug: CDK4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitors with high matching score (≥50%)
Study: 33427211
Drug: CDK4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitors with low matching score (<50%)
Study: 33427211
Drug: CDK4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitors (high matching score)
Study: 33427211
Drug: CDK4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitors (low matching score)
Study: 33427685
Drug: Metformin-containing medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin-containing medication
Study: 33430634
Drug: Extended window
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended window endovascular stroke therapy
Study: 33430807
Drug: PTSD scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTSD scale administered at five-month follow-up
Study: 33430930
Drug: Sedative agents
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative agents (propofol and fentanyl)
Study: 33431018
Drug: Shared Decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared Decision Making (SDM) Antipsychotic Medication Decision Aid
Study: 33432540
Drug: Biosimilar etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biosimilar etanercept 25 mg twice weekly or 50 mg once weekly
Study: 33432547
Drug: SAR341402 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR341402 insulin aspart (SAR-Asp)
Study: 33432547
Drug: NN-Asp (NovoLog®/NovoRapid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN-Asp (NovoLog®/NovoRapid® insulin aspart)
Study: 33433145
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (42 patients)
Study: 33433355
Drug: TGF-β1 (pro-fibrotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-β1 (pro-fibrotic agent)
Study: 33433743
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies involving immune checkpoint inhibitors (CTLA-4, PD-1, PD-L1)
Study: 33433743
Drug: Future approaches
Normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [FUTURE TIME]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Future approaches involving bispecific antibodies and CAR-T cells
Study: 33434161
Drug: rhIGF1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF1 therapy
Study: 33434221
Drug: Corticosteroid immunomodulatory
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid immunomodulatory therapy
Study: 33434221
Drug: IP-10 levels
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP-10 levels exceeding 1,000 pg/mL
Study: 33434290
Drug: Long-term bisphosphonate
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term bisphosphonate therapy in patients with atypical femur fracture (AFF)
Study: 33434290
Drug: Long-term bisphosphonate
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term bisphosphonate therapy in patients without atypical femur fracture (non-AFF)
Study: 33434314
Drug: 80 μg abaloparatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 μg abaloparatide daily
Study: 33435973
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT
Study: 33436023
Drug: Geptanolimab 3
Normalized name: Geptanolimab
DrugBank: Geptanolimab (DB16417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geptanolimab 3 mg/kg intravenously every 2 weeks until disease progression or intolerable toxicity
Study: 33436455
Drug: Average annual
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average annual medication costs per patient
Study: 33436455
Drug: Ratio of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ratio of medication to total health care costs
Study: 33436455
Drug: Medication classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication classes
Study: 33436493
Drug: Alteplase 20
Normalized name: alteplase 20 mg INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 20 mg and 10 mg (combined)
Study: 33436675
Drug: MTf-targeting antibody-drug
Normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTf-targeting antibody-drug conjugate (ADC)
Study: 33436744
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg taken once daily for three months
Study: 33437832
Drug: Twice-daily IVR
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily IVR call reminders with self-management support messaging, plus a weekly IVR adherence assessment
Study: 33437832
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control with only weekly IVR adherence assessment
Study: 33437832
Drug: Twice-daily IVR
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily IVR call reminders
Study: 33438069
Drug: Bevacizumab (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5-15 mg/kg) administered every 2 or 3 weeks, with or without chemotherapy
Study: 33438092
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MEP and MIP measurements.
Study: 33439382
Drug: FLT3 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FLT3 inhibitors
Study: 33439382
Drug: Advanced risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced risk stratification and new treatment strategies
Study: 33439463
Drug: MenACWY-DT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-DT vaccine
Study: 33439866
Drug: tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)
Study: 33439866
Drug: tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: tumor necrosis factor receptor 1 (TNF-R1)
Study: 33441162
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiation therapy (SABR)
Study: 33441449
Drug: Women with
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with concurrent rectal CT
Study: 33443137
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (coiling or BAC)
Study: 33444199
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment with rivaroxaban
Study: 33445952
Drug: Mechanical deligation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical deligation with intravenous recombinant tissue plasminogen activator administered 2 days after deligation
Study: 33445952
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator administered at day 4
Study: 33446655
Drug: NVX-CoV2373 vaccine
Normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 vaccine with saponin-based Matrix-M adjuvant
Study: 33446895
Drug: Exposure and
Normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure and ritual prevention (EX/RP) therapy, 17 sessions, twice weekly
Study: 33447520
Drug: Nucleos(t)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide analogue therapy
Study: 33448286
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) emphasizing parent-led infant-directed singing during NICU hospitalization and across 3 months post-discharge
Study: 33448731
Drug: Daily Truvada
Normalized name: Truvada
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily Truvada (HIV preexposure prophylaxis)
Study: 33448893
Drug: Ofatumumab maintenance
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab maintenance after induction therapy
Study: 33449428
Drug: Targeted Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted Drug Delivery (TDD) for chronic nonmalignant pain
Study: 33449813
Drug: Eprenetapopt (APR-246)
Normalized name: PrameGel Reformulated Apr 2012
DrugBank: Eprenetapopt (DB11684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprenetapopt (APR-246) in combination with azacitidine
Study: 33450367
Drug: Endovascular treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatments in individuals with cerebral infarct
Study: 33451297
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone implant (DEX implant)
Study: 33451780
Drug: Sci-B-Vac® (tri-antigenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sci-B-Vac® (tri-antigenic recombinant Hepatitis B vaccine)
Study: 33453294
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with hyperglycemia (≥140 mg/dl)
Study: 33453294
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with normal glucose levels (<140 mg/dl)
Study: 33454128
Drug: Treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment protocol for phosphate repletion
Study: 33454601
Drug: Immunosuppressant treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressant treatments
Study: 33454817
Drug: Antibiotic-first therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-first therapy
Study: 33455802
Drug: Ropivacaine 0.2%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2%, 200 ml (400 mg) injected peri-articularly in each knee
Study: 33455902
Drug: HeartBot app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HeartBot app intervention for 21 days, 30 minutes daily.
Study: 33459278
Drug: Ghya Bharari
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghya Bharari Ekatra (GBE) intervention delivered over 6 weekly sessions by lay peer educators; included components on relationship quality, resilience, communication, self-esteem, sexual communication, and norms around IPV.
Study: 33460016
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered semaglutide 7 mg
Study: 33460016
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered semaglutide 14 mg
Study: 33461307
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of long chain n-3 polyunsaturated fatty acids (fish oil capsules) for 6 weeks
Study: 33463373
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m²)
Study: 33463384
Drug: Slow and
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow and deep breathing intervention, details on dosage and duration not available.
Study: 33463681
Drug: EHR-integrated digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR-integrated digital health tools (checklist and video) administered on a mobile device via a patient portal or web-based survey at least 24 hours prior to anticipated discharge.
Study: 33464021
Drug: Zidovudine (ZDV),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (ZDV), Lamivudine (3TC), and Lopinavir/Ritonavir (LPV/r) syrup for 48 weeks according to WHO weight band dosing.
Study: 33464147
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab treatment
Study: 33465022
Drug: Traditional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatments (e.g. opioids, NSAIDs)
Study: 33465034
Drug: Behavioral modifications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral modifications due to the pandemic (e.g., using hand sanitizers, avoiding public transport, preferring outdoor venues)
Study: 33468698
Drug: DNA vaccine
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccine pBI-11 targeting HPV16 and HPV18 E6 and E7 proteins
Study: 33468698
Drug: DNA vaccine
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccine pBI-10.1 utilizing native viral sequences